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Summary In the present investigation we have studied the expression of platelet-derived endothelial cell
growth factor/thymidine phosphorylase (PD-ECGF/TP) in ten different human lung carcinoma cell lines, four
small cell carcinomas and six non-small cell carcinomas. None of the small-cell lung carcinoma cell lines
demonstrated expression of PD-ECGF/TP mRNA. However, four of six of the non-small cell carcinoma cell
lines expressed the 1.8 kb PD-ECGF/TP transcript. The cell lines derived from the single squamous cell
carcinoma and the two adenocarcinomas expressed the PD-ECGF/TP mRNA, and were found to have the
corresponding protein both in cell lysates and conditioned media as determined both by immunoblotting and
measurement of thymidine phosphorylase activity. Only one of three studied large cell carcinoma cell lines
expressed low levels of PD-ECGF/TP mRNA, but the corresponding PD-ECGF/TP protein was not demon-
strated by immunoblotting.
Platelet-derived endothelial cell growth factor (PD-ECGF)
was originally characterised as an angiogenesis factor
(reviewed by Miyazono et al., 1991); it was recently found to
have 40% sequence similarity to thymidine phosphorylase of
Escherichia coli, and to have thymidine phosphorylase
activity (Usuki et al., 1992). The amino acid sequence of
platelet-derived endothelial cell growth factor/thymidine
phosphorylase (PD-ECGF/TP), as deduced from a cDNA
clone (Ishikawa et al., 1989), revealed that PD-ECGF/TP
lacks a signal sequence. PD-ECGF/TP has so far been dem-
onstrated in platelets (Miyazono et al., 1987), placenta
(Usuki et al., 1990), and in macrophage-like cells of lung and
liver (Yoshimura et al., 1990). Analysis of expression of
PD-ECGF/TP protein and mRNA in cell lines revealed that
certain epithelial cell lines were positive, including two out of
three thyroid carcinoma cell lines (Usuki et al., 1989).
Human lung cancer can be separated into two major
categories, small cell lung cancer (SCLC) and non-SCLC
(Bunn, 1992). The non-SCLC group can be subdivided into
three morphological entities, squamous cell carincoma
(SQC), adenocarcinoma (ADC) and large cell carcinoma
(LCC) (Histological typing of lung tumours, WHO, Geneva
1981). The distinction between SCLC and non-SCLC is
based on discriminative morphology, biochemical marker
profile and clinical characteristics (Bunn, 1992). The SCLC
group has high levels of a wide spectrum of neuroendocrine
markers (Cuttitta et al., 1985; Gazdar et al., 1985; Baillie-
Johnson et al., 1985; Soderdahl et al., 1988; Bepler et al.,
1987). The non-SCLC group expresses these neuroendocrine
markers at considerably lower levels (Gazdar et al., 1985;
Baillie-Johnson et al., 1985; Bunn, 1992). A heterogeneous
mRNA expression for platelet-derived growth factor (PDGF)
A- and B- chains, and transforming growth factor (TGF) -a
and -P, have been demonstrated in six out of six studied
human non-SCLC cell lines (Soderdahl et al., 1988). The four
studied SCLC cell lines were negative for the expression of
PDGF and TGF-x or -P (Soderdahl et al., 1988). The non-
SCLC cell lines have been demonstrated to induce a
heterogeneous and collagen rich tumour stroma in nude mice
xenografts from the non-SCLC cell lines while the SCLC cell
lines were devoid of this capacity (Bergh, 1988). The stroma
formation may relate to the production of PDGF and TGF-c
or -P or other yet unidentified growth factors with paracrine
activity.
In the present work we report that PD-ECGF/TP is express-
ed in lung adeno- and squamous cell carcinoma cell lines, but
not in the corresponding small cell carcinoma cell lines.
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Materials and methods
Cell culture
The different lung carcinoma cell lines used in this study were
the small-cell lung carcinomas (SCLC) U-1285, U-1690, H-69
and H-82, the large cell lung carcinomas (LCC) U-1810,
H-157 and H-661, the lung adenocarcinomas (ADC) H-23
and H-125, and one squamous cell lung carcinoma (SQC)
U-1752. The cells were grown in RPMI medium supple-
mented with 10% foetal calf serum (FCS) and the anaplastic
thyroid carcinoma cell line was cultured in Eagle's minimum
essential medium with 10% newborn calf serum (NCS).
Antibiotics, 100 U of penicillin and 50 gg streptomycin ml-1,
were added to the medium. The SCLC cell lines were charac-
terised by growth in clusters and the presence of different
neuroendocrine markers according to Table I. The non-
SCLC cell lines grow in monolayer and express epithelial
markers and low levels of neuroendocrine markers (Table I).
Extraction ofRNA
Total RNA was extracted from cells using a lithium chloride/
urea method described by Auffray and Rougeon (1980). Cells
were homogenised in a solution (3 M lithium chloride, 6 M
urea, 0.2% sodium dodecyl sulphate (SDS) and 1 ytI ml-' of
Antifoam A (Sigma Chemicals)) and left on ice overnight.
The cell homogenate was centrifuged for 5 min at 16,000 g
and the pellet was dissolved in a TES-buffer (10 mM
Table I Phenotypic properties of studied cell lines
EGF-rec. In vitro
Cell line Diagnosis NSE mRNA expression growth
Small cell carcinoma cell line
U-1285 SCLC 380 ND Clusters in
suspension
U-1690 SCLC 2100 Attached
H-69 SCLC 817 Clusters in
suspension
H-82 SCLC 317 Clusters in
suspension
Non-small cell carcinoma cell lines
U-1752 SQC < 100 + Monolayer
U-1810 LCC < 100 + Monolayer
H-157 LCC < 100 + Monolayer
H-661 LCC ND - Monolayer
H-23 ADC < 100 + Monolayer
H-125 ADC < 100 + Monolayer
NSE, Neuron-specific enolase in ng/mg protein; EGF-rec.,
epidermal growth factor receptor; ND, not determined.
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triethanolamine pH 7.5, 1 mM EDTA, 0.5% SDS). After an
extraction with phenol followed by an extraction with
chloroform/isoamylalcohol (24:1), the total RNA was
precipitated with 0.1 volumes of 3 M sodium acetate and 2.2
volumes of ethanol. The RNA was quantitated spectrophoto-
metrically and subjected to a poly (A)' selection prior to the
electrophoresis.
Northern blot analysis
Poly (A)' RNA samples (10 .tg/lane) of the different lung
carcinoma cell lines were size-fractionated by electrophoresis
in formaldehyde-agarose and blotted onto a nitrocellulose
filter. The filter was prehybridised for 4 h at 42°C in a buffer
consisting of 20% formamide, S x SSC, S x Denhardt's solu-
tion, 5 mM Na2HPO4, 5 mM NaH2PO4, 0.5% SDS, and
200 jig salmon sperm per ml. Hybridisation was performed
for 8 h at 42°C in the same buffer containing approximately
2 x 106 cpm of 32P-labelled PD-ECGF/TP cDNA probe (PL-
5; 1.5 kb Eco RI fragment; Ishikawa et al., 1989) per ml.
After the hybridisation period the filter was washed in
2 x SSC and 0.5% SDS at 6O°C for 30 min. Autoradiography
was performed at - 70°C in the presence of intensifying
screens (Du Pont).
Immunoblot analysis
Cell cultures were washed with medium and then incubated
in serum-free medium for 24 h. The conditioned medium was
collected and cells were solubilised in 0.15M NaCl, 50 mM
Tris-HCI pH 7.4, 1% Triton X-100, 1% deoxycholate, 0.1%
SDS, 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
150 kallikrein inhibitor units aprotinin per ml, and centri-
fuged at 10,000g for 20 min in order to clarify the samples.
Samples were size fractionated by SDS-electrophoresis using
gradient gels (10-18% acrylamide) and transferred to a nit-
rocellulose filter in a buffer consisting of 10% ethanol,
150 mM glycine, and 20 mM Tris-HCI pH 8.4, at 200 mA. In
order to block the unspecific binding the filters were
incubated in 0.15M NaCl, 10mM Tris-HCl pH 7.4, 5%
bovine serum albumin. The filters were then incubated with
specific PD-ECGF/TP rabbit antiserum (dilution 1:50)
(Miyazono & Heldin, 1989), and washed twice in 0.15 M
NaCl, 10 mM Tris-HCI pH 7.4, followed by two washes in
0.15 M NaCl, 10 mM Tris-HCI pH 7.4, 0.05°% Triton X-100.
The filters were then incubated for 30 min with swine anti-
rabbit IgG diluted 1:1000 in 0.15 M NaCl, 10mM Tris-HCI
pH 7.4, and 0.1% bovine serum albumin. After washing as
described above, the staining was performed with
100 mg ml-' nitrobluetetrazolium, 40 tg ml-' of 5-bromo-4-
chloro-3-indolyl phosphate, 5 mM MgCI2, 0.1 M ethanolamine
buffer, pH 9.6.
Thymidine phosphorylase assay
Lysates were prepared from the cell lines by freeze-thawing
cells 5 times in a buffer consisting of 50 mM Tris-HCI, pH
7.4, 0.15 M NaCl, and centrifuged for 15 min at 10,000g. The
cell lysates were incubated for 16 h at 37°C in 5 mM
thymidine and 10 mM K3PO4, pH 7.4. At the end of incuba-
tion 0.3 ml of the reaction-mix was added to 0.7 ml of 0.5 M
NaOH. The conversion of thymidine to thymine was
measured spectrofotometrically at 300 nm (Schwartz, 1978).
The thymidine phosphorylase activity found is expressed as
the change in optical density at 300 nm (A mOD300) per mg
of protein in the cell lysates.
Results and discussion
Northern blot analysis of poly (A)' RNA extracted from the
different cell lines showed an expression of PD-ECGF/TP
transcripts in four of six of the non-SCLC cell lines (Figure
1). The positive cell lines were the two adenocarcinomas
(H-23 and H-125), the squamous cell lung carcinoma (U-
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Figure 1 Expression of PD-ECGF/TP mRNA. Poly (A)' RNA
samples (10fig/sample) were electrophoresed, blotted and hyb-
ridised with a PD-ECGF cDNA probe. A photograph of the
resulting autoradiogram is shown. An anaplastic thyroid car-
cinoma cell line, HTh 7, was used as a positive control for the
expression of PD-ECGF/TP mRNA (Usuki et al., 1989).
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Figure 2 PD-ECGF/TP protein in ADC and SQC lung car-
cinomas. Conditioned media and lysates of the different lung
carcinoma cell lines were subjected to immunoblotting, using a
polyclonal PD-ECGF rabbit antiserum. Immunoglobulin com-
plexes were visualised by alkaline phosphatase staining. Pure
PD-ECGF/TP (100 ng) was used as control in the experiment. All
lung carcinoma cell lines were analysed, but only the positive cell
lines are shown in the figure.
1752), as well as one of the three large cell lung carcinomas
(U-1810). There was a marked difference in the amount of
PD-ECGF/TP mRNA in the positive cell lines. As seen in
Figure 1, the PD-ECGF/TP probe also hybridised to several
mRNA's of different sizes in all studied cell lines except for
the thyroid carcinoma cell line. So far three different PD-710 N.-E. HELDIN et al.
Table II PD-ECGF/TP mRNA, protein and thymidine phosphorylase activity in lung
carcinoma cell lines
PD-ECGF/TP Thymidine phosphorylase
mRNA Protein activity
cell lysate cond. medium (A mOD300mg-' protein)
Cell line
SCLC U-1285 - - - 4
U-1690 - - - II
H-69 - - - 3
H-82 - - - I
SQC U-1752 + + - 33
LCC U-1810 (+) - - 26
H-157 - - - 2
H-661 - - - 21
ADC H-23 + + + + + 192
H-125 ++ + + + 188
Thyr. ca. HTh 7 + + + + + 230
-, (+), + and + +: relative expression of mRNA and protein. Thymidine phosphorylase
activity is expressed in the table as the difference in optical density at 300 nm (A mOD300)
between control and samples incubated as described in Materials and methods. The
anaplastic thyroid carcinoma cell line HTh 7 was used as positive control.
ECGF/TP transcript sizes have been identified (1.8, 3.0 and
3.2 kb) (Ishikawa et al., 1988; Usuki et al., unpublished
results), and the nature of the cross-hybridising large trans-
cript found in the lung carcinomas is still unknown. In
immunoblot analysis using a polyclonal rabbit PD-ECGF/TP
antiserum, a 45 kDa PD-ECGF/TP protein was detected in
the lysates of H-23, H-125 and U-1752 cells (Figure 2).
However, the protein could not be detected in a cell lysate
from U-1810 even though this cell line expressed low
amounts of PD-ECGF/TP mRNA. PD-ECGF/TP protein
was mainly detected in the cell lysates rather than in the
conditioned media which is consistent with the lack of signal
sequence in the protein, and with previous results (Usuki et
al., 1989). However, some PD-ECGF/TP immunoreactivity
was also found in the conditioned media of the H-23 and
H-125 cell lines, the two cell lines with the highest PD-
ECGF/TP mRNA level (Figure 2). The PD-ECGF/TP pro-
tein found in the conditioned medium was possibly derived
from dying or dead cells. The phosphorylase activity found
in cell lysates from the different cell lines correlated well to
the expression of PD-ECGF/TP mRNA and protein; a high
phosphorylase activity was found in H-23 and H-125 lysates.
However, we were unable to detect any thymidine phos-
phorylase activity in conditioned medium from the cell lines.
Our results are summarised in Table II.
PD-ECGF/TP seems to be more frequently expressed in
more differentiated types of human non-SCLC cell lines. The
one exception found in this study is the LCC cell line U-
1810. The predominant expression in SQC and ADC may
indicate that the PD-ECGF/TP gene is switched on together
with other genes related to SQC/ADC differentiation. Thus,
PD-ECGF/TP may be a useful marker for the differential
diagnosis of lung carcinoma.
The function of PD-ECGF/TP in the human non-SCLC
group remains to be elucidated. Expression of transduced
PD-ECGF/TP in ras-transformed 3T3 cells leads to a marked
increase in the angiogenic response in the nude mouse
(Ishikawa et al., 1989). It is interesting to speculate that the
synthesis of PD-ECGF/TP in lung carcinoma cells contribute
in the process of neovascularisation.
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